1 / 9

Chemotherapy-induced Nausea and Vomiting (CINV) Market Expected to Reach $2,659 Million, Globally, By 2022

Growth in number of patients undergoing chemotherapy drugs treatment and introduction of new drug delivery methods to improve patient compliance are the major factors that significantly impact the growth of the CINV market.

alliedmarketresearch
Download Presentation

Chemotherapy-induced Nausea and Vomiting (CINV) Market Expected to Reach $2,659 Million, Globally, By 2022

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chemotherapy-induced Nausea and Vomiting (CINV) Market Opportunities and Forecasts, 2014- 2022 PUBLISHED DATE: 18-Jan-17

  2. Increase in adoption of chemotherapeutic drugs is directly linked to the growth of the CINV drugs market. It is estimated that in 2016, approximately 1.6 million new cases of cancer will be diagnosed with breast, lung, and bronchus cancer. • It is observed that approximately 35% of patients experienced nausea within 24 hours of chemotherapy, while 54% suffered from nausea and 34% experienced vomiting after 24 hours. • Growth in number of patients undergoing chemotherapy drugs treatment and introduction of new drug delivery methods to improve patient compliance are the major factors that significantly impact the growth of the CINV market. • At present, pharmaceutical companies are increasingly investing in the R&D of CINV drugs to offer better chemotherapy drugs and increase their market share. • The needle free, painless, and cost-effective transdermal delivery system is expected to witness increase in demand in global CINV market. CINV MARKET-INTRODUCTION

  3. CINV MARKET-KEY FINDINGS • The Aloxi segment generated highest revenue in the global market in 2015, accounting for over half of the total market. • The Netupitant-Palonosetron FDC segment is the fastest growing segment at a CAGR of 10.8%.

  4. TABLE OF CONTENTS • INTRODUCTION •   EXECUTIVE SUMMARY •  MARKET OVERVIEW • CINV MARKET BY PATIENT POOL • CINV MARKET BY GEOGRAPHY •  COMPANY PROFILES

  5. SEGMENT OVERVIEW-CINV MARKET

  6. ASIA-PACIFIC CINV MARKET, 2014-2022 ($MILLION)

  7. CINV MARKET- BY GEOGRAPHY  North America, Europe, Asia Pacific, LAMEA

  8. COMPANYPROFILES GlaxoSmithKline plc Helsinn Holding S.A Heron Therapeutics Merck & Co Tesaro

  9. THANK YOU Thank You! For More Details Visit us at https://www.alliedmarketresearch.com/cinv-market Follow Us On

More Related